LifeStance Health Group, Inc. (NASDAQ: LFST) reported its fourth‑quarter and full‑year 2025 financial results on February 25, 2026. The company posted revenue of $382.2 million, up 17% year‑over‑year, beating the consensus estimate of $378.45 million by $3.75 million. The revenue growth was driven by a 18% increase in visit volumes and a 15% expansion in the clinician network, which lifted the average revenue per visit and helped offset modest pricing pressure in some specialty services.
Earnings per share for the quarter were $0.03, a beat of the consensus estimate of $0.05, but a miss relative to the $0.00 estimate that some analysts had used. The $0.03 EPS was achieved through disciplined cost management and improved operating leverage, which lifted the adjusted EBITDA margin to 12.8% from 10.2% in the prior year. The company’s adjusted EBITDA for Q4 2025 was $49.1 million, up 12% from $44.0 million in Q4 2024, reflecting higher visit volumes and a favorable mix of high‑margin specialty services.
For the full year, LifeStance generated $1.251 billion in revenue, a 14% increase from $1.151 billion in 2024. Net income for the year was $0.03 per share, marking the first positive net income for the company and underscoring the cumulative effect of quarterly improvements. Adjusted EBITDA for the year reached $185 million, a 15% rise from $159 million in 2024, and the company’s center margin grew to $126.3 million, representing 33.0% of total revenue, up 15% from the prior year.”,
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.